David E. Lanfear, MD MS
@dlanfearMD
Followers
212
Following
86
Media
11
Statuses
72
Vice President of Research and Chief Scientific Officer, Henry Ford Health. Co-director, Center for Individualized and Genomic Medicine Research
Joined October 2021
RT @DukeHFDoc: Great kick off to #COMET-HF North American Investigator Meeting from @MyosinMD focused on the science behind omecamtiv mecar….
0
2
0
RT @JasmineLuzum: A genetic variant in GRK4 significantly interacts with beta-blocker benefit in patients heart failure (and possibly other….
0
3
0
RT @JennaSkowronski: Really happy to share our introductory guide to cardio-obstetrics in the CCU! We hope this will contribute to excepti….
0
15
0
RT @tomlumbers: Exciting news! Our latest research on dilated cardiomyopathy has just been published in Nature Genetics: .
hermesconsortium.org
An international collaboration to investigate the genetic basis of heart failure
0
3
0
RT @CircHF: Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations @JulioChirinosMd @dlanfearMD @DrNancySweitz….
0
7
0
RT @AH_AlbertHenry: 🚨 Our latest GWAS of heart failure subtypes is now out in Nature Genetics! . A massive global….
0
7
0
RT @JeffTeuteberg: Congestion🚰 assessment in HF: from symptoms, to weights, BNP, invasive pressures. now IVC area? Check out this and o….
0
16
0
Exciting times: HFH+MSU Health Science Research Building ground breaking. Congrats to our great HFH leaders, @SteveKalkanisMD , Adnan Munkarah MD, Robert Riney, and all our MSU partners.
0
0
4
Honored to be part of this fantastic randomized trial showing similar benefits of home-based cardiac rehab vs. traditional. Thanks to steve, clinton and the whole preventive cardiology crew for letting be a part.
0
7
24
RT @CMichaelGibson: I’m proud to announce Dr. Jim Januzzi’s promotion to Chief Scientific Officer @BaimInstitute (formerly Harvard Clinical….
0
35
0
RT @JasmineLuzum: Nice overview of #pharmacogenetic recommendations in clinical practice guidelines for multiple therapeutic areas: cardiol….
academic.oup.com
AbstractPurpose. Pharmacogenetic testing can identify patients who may benefit from personalized drug treatment. However, clinical uptake of pharmacogeneti
0
2
0
RT @CardioTrasNB: Our turn! Today our PI is sharing latest findings in mitral valve disease biomarkers and omics at the #Biomarkers forum .….
0
6
0
Outstanding work by Isabella Kardys, Marie de Bakker and friends, demonstrating proteomic derived panel outperforms clinical risk factors.
0
0
2
Outstanding work by Isabella Kardys and crew. Congrats!. Machine learning–based biomarker profile derived from 4210 serially measured proteins predicts clinical outcome of patients with heart failure
academic.oup.com
AbstractAims. Risk assessment tools are needed for timely identification of patients with heart failure (HF) with reduced ejection fraction (HFrEF) who are
0
0
1
RT @robdeedo: Now this is how to do an assessment of value for pharmacists' services! We need more formal CEAs like this based on patient o….
jamanetwork.com
This economic evaluation estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US.
0
10
0
RT @ReeseClarett13: I can go back and forth with the Michigan and OSU banter. It’s fun and comical on lots of levels. I can take the jokes….
0
565
0
RT @JasmineLuzum: Now published in @CircHF: Common Variants in FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Hear….
0
3
0
RT @RyanTedfordMD: Made it to South Korea and fired up for Heart Failure Seoul 2023/CTC Asia 2023! Especially excited about the @HFSA @ks….
0
6
0